EUVIMEDEUVIMED entdecken
Crossref

Neuroleptic malignant syndrome in the Emergency Department

Carlos-Javier Moreno-Pérez, Ángela Pieras-López, Marta Duero-Adrados

Emergencias Pediátricas · 26.06.2026 · 5 (2) · 23-29

DOI: 10.65350/emped.v5n2.en.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Emergencias Pediátricas, online erschienen am 26.06.2026. Verfasst von Carlos-Javier Moreno-Pérez und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neuroleptic malignant syndrome (NMS) is a severe, rare adverse reaction associated with the use of neuroleptics. Its pathophysiology is related to central dopaminergic blockade, affecting thermoregulation, muscle tone, and the autonomic nervous system.Epidemiology: More prevalent in adults, pediatric cases have been reported, especially in males treated with typical or atypical antipsychotics. Its incidence is low but might be underestimated.Risk factors: These include pharmacological aspects (high doses, rapid titration, polypharmacy), intrinsic patient factors (neurological comorbidities, family history), and environmental factors (dehydration, immobilization, infections).Clinical presentation: Fever, rigidity, altered mental status, and autonomic instability may appear. It can progress to rhabdomyolysis, renal failure, and metabolic disturbances.Diagnosis: It is clinical, based on criteria such as those of Levenson, Lazarus, and the DSM-5. It requires the exclusion of other entities like serotonin syndrome, malignant catatonia, or meningitis.Treatment: It requires discontinuation of the neuroleptic, intensive support (hydration, temperature control, ventilation, electrolyte correction), and specific treatment with dantrolene and bromocriptine. Benzodiazepines can be useful as adjuvant therapy.Neuroleptic reintroduction: It must be done with caution, using low doses and avoiding the parenteral route.

Conclusion

NMS demands early diagnosis and multidisciplinary management. In pediatrics, its presentation may be atypical, so it should be considered following any change in neuroleptic treatment.

Zitieren

APA

Moreno-Pérez, C., Pieras-López, Á., & Duero-Adrados, M. (2026). Neuroleptic malignant syndrome in the Emergency Department. Emergencias Pediátricas, 5(2), 23-29. https://doi.org/10.65350/emped.v5n2.en.005

Vancouver

Moreno-Pérez C, Pieras-López Á, Duero-Adrados M. Neuroleptic malignant syndrome in the Emergency Department. Emergencias Pediátricas. 2026;5(2):23-29. doi:10.65350/emped.v5n2.en.005

BibTeX
@article{MorenoPrez2026,
  author = {Moreno-Pérez, Carlos-Javier and Pieras-López, Ángela and Duero-Adrados, Marta},
  title = {Neuroleptic malignant syndrome in the Emergency Department},
  journal = {Emergencias Pediátricas},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {23--29},
  doi = {10.65350/emped.v5n2.en.005}
}
Kostenlos starten →